» Articles » PMID: 22402283

Endothelial RIG-I Activation Impairs Endothelial Function

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2012 Mar 10
PMID 22402283
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Endothelial dysfunction is a crucial part of the chronic inflammatory atherosclerotic process and is mediated by innate and acquired immune mechanisms. Recent studies suggest that pattern recognition receptors (PRR) specialized in immunorecognition of nucleic acids may play an important role in endothelial biology in a proatherogenic manner. Here, we analyzed the impact of endothelial retinoic acid inducible gene I (RIG-I) activation upon vascular endothelial biology.

Methods And Results: Wild type mice were injected intravenously with 32.5 μg of the RIG-ligand 3pRNA (RNA with triphosphate at the 5'end) or polyA control every other day for 7 days. In 3pRNA-treated mice, endothelium-depended vasodilation was significantly impaired, vascular oxidative stress significantly increased and circulating endothelial microparticle (EMP) numbers significantly elevated compared to controls. To gain further insight in RIG-I dependent endothelial biology, cultured human coronary endothelial cells (HCAEC) and endothelial progenitor cells (EPC) were stimulated in vitro with 3pRNA. Both cells types express RIG-I and react with receptor upregulation upon stimulation. Reactive oxygen species (ROS) formation is enhanced in both cell types, whereas apoptosis and proliferation is not significantly affected in HCAEC. Importantly, HCAEC release significant amounts of proinflammatory cytokines in response to RIG-I stimulation.

Conclusion: This study shows that activation of the cytoplasmatic nucleic acid receptor RIG-I leads to endothelial dysfunction. RIG-I induced endothelial damage could therefore be an important pathway in atherogenesis.

Citing Articles

The FKBPL-based therapeutic peptide, AD-01, protects the endothelium from hypoxia-induced damage by stabilising hypoxia inducible factor-α and inflammation.

Ghorbanpour S, Cartland S, Chen H, Seth S, Ecker R, Richards C J Transl Med. 2025; 23(1):309.

PMID: 40069829 PMC: 11895374. DOI: 10.1186/s12967-025-06118-w.


Alterations in genes associated with cytosolic RNA sensing in whole blood are associated with coronary microvascular disease in SLE.

Huo L, Kumar A, Tumurkhuu G, Bose M, Berman D, Wallace D Sci Rep. 2025; 15(1):2457.

PMID: 39828802 PMC: 11743764. DOI: 10.1038/s41598-024-82190-4.


Harnessing innate immune pathways for therapeutic advancement in cancer.

Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y Signal Transduct Target Ther. 2024; 9(1):68.

PMID: 38523155 PMC: 10961329. DOI: 10.1038/s41392-024-01765-9.


Superfamily II helicases: the potential therapeutic target for cardiovascular diseases.

Fang T, Wang X, Huangfu N Front Cardiovasc Med. 2023; 10:1309491.

PMID: 38152606 PMC: 10752008. DOI: 10.3389/fcvm.2023.1309491.


Thymidine phosphorylase facilitates retinoic acid inducible gene-I induced endothelial dysfunction.

Baris A, Fraile-Bethencourt E, Eubanks J, Khou S, Anand S Cell Death Dis. 2023; 14(4):294.

PMID: 37100811 PMC: 10131517. DOI: 10.1038/s41419-023-05821-0.